Innate Pharma’s (IPHA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Innate Pharma (NASDAQ:IPHA) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $11.50 price target on the stock.

Separately, Evercore ISI raised shares of Innate Pharma to a “strong-buy” rating in a research report on Monday, September 16th.

Innate Pharma Price Performance

Shares of Innate Pharma stock traded down $0.12 during trading hours on Tuesday, hitting $1.55. The company’s stock had a trading volume of 7,494 shares, compared to its average volume of 9,015. Innate Pharma has a 1-year low of $1.52 and a 1-year high of $3.15. The business has a fifty day moving average of $2.04 and a 200 day moving average of $2.24.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.